全文获取类型
收费全文 | 3579篇 |
免费 | 190篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 127篇 |
妇产科学 | 52篇 |
基础医学 | 538篇 |
口腔科学 | 90篇 |
临床医学 | 191篇 |
内科学 | 633篇 |
皮肤病学 | 63篇 |
神经病学 | 276篇 |
特种医学 | 229篇 |
外科学 | 424篇 |
综合类 | 58篇 |
预防医学 | 357篇 |
眼科学 | 83篇 |
药学 | 327篇 |
中国医学 | 8篇 |
肿瘤学 | 256篇 |
出版年
2023年 | 21篇 |
2022年 | 14篇 |
2021年 | 65篇 |
2020年 | 41篇 |
2019年 | 77篇 |
2018年 | 80篇 |
2017年 | 80篇 |
2016年 | 84篇 |
2015年 | 83篇 |
2014年 | 129篇 |
2013年 | 144篇 |
2012年 | 257篇 |
2011年 | 238篇 |
2010年 | 135篇 |
2009年 | 113篇 |
2008年 | 194篇 |
2007年 | 188篇 |
2006年 | 217篇 |
2005年 | 201篇 |
2004年 | 159篇 |
2003年 | 152篇 |
2002年 | 119篇 |
2001年 | 67篇 |
2000年 | 62篇 |
1999年 | 58篇 |
1998年 | 18篇 |
1994年 | 14篇 |
1993年 | 16篇 |
1992年 | 51篇 |
1991年 | 43篇 |
1990年 | 47篇 |
1989年 | 48篇 |
1988年 | 38篇 |
1987年 | 35篇 |
1986年 | 30篇 |
1985年 | 21篇 |
1984年 | 26篇 |
1983年 | 20篇 |
1979年 | 25篇 |
1977年 | 18篇 |
1975年 | 16篇 |
1974年 | 18篇 |
1973年 | 20篇 |
1972年 | 18篇 |
1971年 | 21篇 |
1970年 | 21篇 |
1968年 | 15篇 |
1967年 | 20篇 |
1966年 | 17篇 |
1933年 | 13篇 |
排序方式: 共有3781条查询结果,搜索用时 62 毫秒
71.
Levente Bodoki Melinda Vincze Zoltán Griger Tamás Csonka Balázs Murnyák Andrea Kurucz Katalin Dankó Tibor Hortobágyi 《Central European Journal of Medicine》2014,9(1):80-85
Inclusion body myositis is a slowly progressive myopathy affecting predominantly the middle-aged and older patient population. It is a major form of the idiopathic inflammatory myopathies which are chronic systemic autoimmune diseases characterized by symmetrical proximal muscle weakness. Unfortunately, there is no effective therapy yet; however, the early diagnosis is essential to provide treatment options which may significantly slow the progression of the disease. In our case-based clinicopathological study the importance of the close collaboration between the clinician and the neuropathologist is emphasised. 相似文献
72.
Zucchini S Pirazzoli P Baronio F Gennari M Bal MO Balsamo A Gualandi S Cicognani A 《The Journal of clinical endocrinology and metabolism》2006,91(11):4271-4276
CONTEXT: GH replacement therapy in GH-deficient (GHD) patients is usually continued until adult height despite the fact that most of these subjects display a normal secretion when retested at the end of growth. Puberty is the most likely time for normalization of GH secretion. OBJECTIVES: The objectives of this study are to establish the characteristics and the percentage of the subjects with isolated GHD who normalized secretion at puberty and to compare their statural outcomes with those of the subjects with persistent deficiency treated also after retesting. DESIGN AND SETTING: This was a prospective, nonrandomized, open-label study conducted in a university research hospital. PATIENTS AND INTERVENTION: Sixty-nine subjects (40 male, 29 female) with a diagnosis before puberty of isolated GHD by means of arginine and l-dopa tests were reevaluated with the same tests after at least 2 yr of therapy and after puberty onset. If GH peak at retesting was more than 10 microg/liter, therapy was withdrawn. MAIN OUTCOME MEASURES: Percentage and characteristics of normalized subjects at retesting, outcome of treatment in the subjects treated or untreated to adult height, and factors predictive of growth outcome were measured. RESULTS: At retesting, 44 subjects (63.7%) confirmed a GH peak less than 10 microg/liter (24 of 40 male and 20 of 29 female). Apart from a less delayed bone age at diagnosis in females, the subjects with confirmed GHD were not different at diagnosis from the other group for height deficit at diagnosis, first year growth response to GH, age and height at puberty onset, height, and IGF-I at retesting. Mean adult height was 165.1 +/- 4.5 cm in the male group treated until adult height vs. 164.0 +/- 3.4 cm in the group who suspended therapy at retesting. Mean adult height was 153.2 +/- 4.1 cm in the female group treated until adult height vs. 152.9 +/- 5.2 cm in the group that suspended therapy at retesting. As regards the parameters expressing the final outcome, the only difference was found in the mean increment adult height-target height sd score in favor of the male group treated until adult height. In both sexes, therapy duration and GH levels at diagnosis and at retesting were unrelated to adult height parameters and to height increments during the period of observation. CONCLUSIONS: One third of our GHD subjects diagnosed before puberty presented a normal secretion at puberty. The withdrawal of GH therapy in these subjects after retesting was not associated with a catch down growth, and they obtained an adult height similar to those obtained by the GHD subjects treated until adult height. It seems convenient, in subjects with nonsevere GHD, to retest GH secretion at midpuberty and to withdraw treatment for the subjects that are no longer deficient. 相似文献
73.
G. L. Lukács I. Zs.-Nagy Gy. Lustyik Gy. Balázs 《Journal of cancer research and clinical oncology》1983,105(3):280-284
Summary Parallel studies were performed using microfluorimetric DNA determination and X-ray microanalysis on the same thyroid biopsy material to compare the intranuclear DNA and monovalent electrolyte contents (Na+, K+, Cl–). Samples were taken from apparently healthy, adenomatous, and cancerous parts of human thyroid glands removed surgically. The time interval was less than 1 min. The tissues were classified by the pathologist into four main classes: 1) Normal thyroid tissue; 2) benign adenomas; 3) differentiated (follicular and papillary) carcinomas; and 4) anaplastic cancers. The results revealed that the level of aneuploidization showed an increase parallel with the malignancy of the studied tumor. At the same time, a similar tendency was found in the average values of the intranuclear Na+:K+ ratios. The results obtained in this way confirm the possibility that the electric properties of the cell membrane, that is the sustained membrane depolarization, may have a role in the regulation of DNA synthesis and in mitogenesis. These results may offer new diagnostic and/or therapeutic possibilities. 相似文献
74.
Five cases of giant inflammatory polyps associated with idiopathic inflammatory bowel disease are reported. Polyps produced intestinal obstruction in three cases; consequently, surgery was performed. In a further two cases, intestinal bleeding was improved by endoscopic polypectomy. Electron microscopy showed fibroblasts, myofibroblasts, mast cells, lymphocytes, collagen fibers, capillaries, and venules. Remnants of the original mucosal epithelial cells, smooth muscle cells, and hypertrophic autonomous nerve plexuses were noted. Nerve fibers were interwoven with the matrix of the polyps. Mast cells were closely linked with vessels, nerves, and collagen fibers. They may have an important role in the excessive granulation, angiogenesis, and fibrotic process in giant inflammatory polyps. 相似文献
75.
76.
Vitamin E-based therapy is effective in ameliorating transaminasemia in nonalcoholic fatty liver disease. 总被引:3,自引:0,他引:3
Kaushal Madan Yogesh Batra Datta S Gupta Bal Chander K D Anand Rajan Rajvir Singh S K Panda S K Acharya 《Indian journal of gastroenterology》2005,24(6):251-255
BACKGROUND: Comparative trials of ursodeoxycholic acid (UDCA), vitamin E and weight management programs among patients with nonalcoholic fatty liver disease (NAFLD) are lacking. AIM: To find an effective single agent or combination of agents for management of NAFLD. METHODS: In this retrospective study, consecutive patient with histologically confirmed NAFLD with raised ALT were included. The patients received either weight management (exercise and therapeutic lifestyle changes [TLC] diet with a target to reduce body weight 10% in 6 months) (group I) ; weight management + UDCA (300 mg BID) (group II); or weight management + UDCA + vitamin E (400 mg OD) (group III). Outcome measure was normalization of ALT. RESULTS: 42 patients (18, 12 and 12 in groups I, II and III, respectively) were included between 1996 and 2004. All patients in group III normalized their ALT levels, which was significantly higher than numbers in group I (8/18) and group II (5/12); (p=0.003). Post treatment ALT was significantly lower in group III (28.6 [9.3]) as compared to group I (59.3 [32.2]) and group II (49.0[31.8]); (p=0.01). Type of therapy received was the only factor predictive of ALT normalization. CONCLUSION: Combination regimen containing vitamin E appears to be effective in normalizing ALT among NAFLD patients. 相似文献
77.
Stenting for restenotic lesions with the BARD XT stent 总被引:1,自引:0,他引:1
Rahel BM Suttorp MJ Te Riele HA Bal ET Ernst SM Mast EG Ten Berg JM Kelder JC Plokker HW 《Journal of interventional cardiology》2003,16(3):227-230
BACKGROUND: Conventional PTCA for the treatment of restenotic lesions is associated with a high rate of recurrence (30-50%). Primary stenting decreases the restenosis rate at long-term follow-up. METHODS: One-hundred consecutive patients with restenosis received a Bard XT stent. Follow-up angiography was performed after 6 months. Angiograms were compared by means of computed quantitative analysis. RESULTS: The mean pretreatment reference diameter was 2.88 +/- 0.51 mm. The mean minimal luminal diameter (MLD) increased from 1.09 +/- 0.57 mm to 2.70 +/- 0.44 mm. The percent diameter stenosis decreased from 66 +/- 13% to 15 +/- 10%. The procedural success rate was 99%. At 6 month follow-up repeat angiography was performed in 86 patients. The mean MLD was 1.74 +/- 0.67 mm with a mean diameter stenosis of 41 +/- 20%. Residual anginal complaints were reported in 29% of patients. In-stent restenosis (defined as diameter stenosis of more than 50%) occurred in 18% of the patients. CONCLUSION: Placement of the Bard XT stent in restenotic lesions is feasible, has an excellent short term outcome and yields a favorable result at 6 month follow-up angiography. 相似文献
78.
Background and study aims
Occult hepatitis B infection (OBI) is known to be mostly prevalent in chronic hepatitis C (CHC) patients and OBI reactivation might be life-threatening in patients undergoing interferon (IFN)-free direct acting antiviral (DAA) therapy. As previous studies have revealed a relationship between OBI and non-response to IFN-based antiviral therapy, the aim of the current study was to determine if there was a higher prevalence of OBI in IFN non-responders than responders.Patients and Methods
This retrospective cross-sectional study was conducted in CHC patients who had previously received IFN-based antiviral therapy. Serum samples of 100 HBsAg negative CHC patients were tested for HBV DNA, anti-HBc IgG, anti-HBs, ALT and AST. The presence of OBI was compared between 50 IFN responders and 50 IFN non-responders. Patients with a history of previous HBV infection, patients with evidence of cirrhosis and patients who had received IFN therapy within the last one year were excluded from the study.Results
Anti-HBc IgG positivity was determined in 53% of the patients. HBV DNA positivity, indicating OBI was determined in 1 (1%) patient. This patient was anti-HBc IgG positive, anti-HBs negative, ALT and AST levels were normal. The HBV DNA and anti-HBc IgG positivity rates were higher in the non-responder group than in the responder group, but the difference was not statistically significant (p?=?0.31 and p?=?0.07 respectively).Conclusion
According to the results of this study, the prevalence of OBI is lower than expected amongst CHC patients in Turkey and it may not be necessary to apply routine screening to IFN non-responders for OBI infection before DAA therapy. However, there is a need for multicentre studies with larger patient series. 相似文献79.